Surfix Diagnostics

Surfix Diagnostics develops diagnostic tests for the early detection and monitoring of cancer utilizing its photonic diagnostics platform that combines six state-of-the-art technologies. To make it even more exciting: this photonic diagnostics platform is so versatile that it can be used for immunoassays AND for molecular diagnostics. Any protein or nucleic acid-based biomarker in a liquid biopsy can be detected, provided a suitable bioreceptor to capture this biomarker is available. The core of Surfix’s photonic diagnostics platform is a photonic biosensor consisting of a photonic biochip and a microfluidic cartridge both optimized with Surfix's proprietary nanocoatings. The biosensor is used in combination with a dedicated desktop reader.